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Abstract
Background: The proteolytic maturation of the nuclear protein lamin A by the zinc metalloprotease ZMPSTE24 is critical for
human health. The lamin A precursor, prelamin A, undergoes a multi-step maturation process that includes CAAX
processing (farnesylation, proteolysis and carboxylmethylation of the C-terminal CAAX motif), followed by ZMPSTE24-
mediated cleavage of the last 15 amino acids, including the modified C-terminus. Failure to cleave the prelamin A ‘‘tail’’, due
to mutations in either prelamin A or ZMPSTE24, results in a permanently prenylated form of prelamin A that underlies the
premature aging disease Hutchinson-Gilford Progeria Syndrome (HGPS) and related progeroid disorders.
Methodology/Principal Findings: Here we have investigated the features of the prelamin A substrate that are required for
efficient cleavage by ZMPSTE24. We find that the C-terminal 41 amino acids of prelamin A contain sufficient context to allow
cleavage of the tail by ZMPSTE24. We have identified several mutations in amino acids immediately surrounding the
cleavage site (between Y646 and L647) that interfere with efficient cleavage of the prelamin A tail; these mutations include
R644C, L648A and N650A, in addition to the previously reported L647R. Our data suggests that 9 of the 15 residues within
the cleaved tail that lie immediately upstream of the CAAX motif are not critical for ZMPSTE24-mediated cleavage, as they
can be replaced by the 9 amino acid HA epitope. However, duplication of the same 9 amino acids (to increase the distance
between the prenyl group and the cleavage site) impairs the ability of ZMPSTE24 to cleave prelamin A.
Conclusions/Significance: Our data reveals amino acid preferences flanking the ZMPSTE24 cleavage site of prelamin A and
suggests that spacing from the farnesyl-cysteine to the cleavage site is important for optimal ZMPSTE24 cleavage. These
studies begin to elucidate the substrate requirements of an enzyme activity critical to human health and longevity.
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Introduction
The premature aging disease Hutchinson-Gilford Progeria
Syndrome (HGPS) and related progeroid disorders are caused
by defective processing of the lamin A precursor, prelamin A [1,2].
Lamins are intermediate filament proteins that form a network of
polymerized proteins that underlies the nuclear envelope. The
nuclear lamins regulate the structure and shape of the nucleus, and
provide an organizing platform for heterochromatin, transcription
factors and nuclear pore complexes [3,4]. There are two types of
lamins, A-type (comprising the splice isoforms lamin A and C), and
B-type (lamin B1, B2). All lamins, with the exception of lamin C,
undergo post-translational modification of their C-terminal CAAX
motif (in which C is cysteine, A is often aliphatic, and X is any
residue), an event thought to be integral to their localization and
function at the nuclear envelope [5,6]. Modification of the CAAX
motif involves an ordered series of events that includes farnesyla-
tion of the CAAX cysteine, endoproteolytic removal of the
terminal three (AAX) residues, and finally carboxylmethylation of
the farnesyl-cysteine. CAAX modification and the enzymes
involved are shown for the lamin A precursor, prelamin A, in
Figure 1A (steps 1–3). While the farnesyltransferase (FTase) is a
soluble enzyme, the enzymes RCE1, ZMPSTE24 and ICMT are
integral membrane proteins that reside in the endoplasmic
reticulum (ER) and also in the inner nuclear membrane (INM)
[6–8].
The hydrophobic post-translational modifications appended to
the CAAX cysteine (farnesyl and carboxylmethyl groups) are
thought to help anchor the lamins to the lipid bilayer of the INM,
at least initially. However, while B-type lamins retain their farnesyl
and methyl modifications, lamin A does not [9,10]. Subsequent to
CAAX modification of the C-terminus of prelamin A, the 15
amino acid long ‘‘tail’’ of prelamin A is endoproteolytically cleaved
off, releasing mature lamin A (Figure 1A, step 4). The enzyme that
mediates this cleavage step is ZMPSTE24, a multispanning
membrane Zn
++ metalloprotease [11,12]. Prelamin A is the only
known mammalian substrate for ZMPSTE24. Interestingly,
ZMPSTE24 plays dual roles in lamin A maturation, both in 1)
AAX’ing (endoproteolyis of the CAAX motif; Figure 1A, step 2), a
role in which it is functionally redundant with RCE1, and in 2) tail
cleavage, a role in which ZMPSTE24 is uniquely required
(Figure 1A, step 4) [5,13,14].
The purpose of removing the modified tail from prelamin A is
not clear, but failure to do so is associated with progeroid disorders
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diseases, in order of increasing severity, include metabolic disorder
(MD) [15], mandibuloacral dysplasia type B (MAD-B) [16],
Hutchinson-Gilford Progeria Syndrome (HGPS) [1,2,17], and the
neonatal lethal restrictive dermopathy (RD) [18,19]. These
diseases are caused by mutations that map to genes encoding
either lamin A, or the enzyme ZMPSTE24, that result in a partial
or full block in cleavage of the CAAX-modified prelamin A tail.
HGPS is the most well-known and best-studied of these diseases
[17,20,21]. HGPS is a devastating premature aging disease
resulting from a mutation that activates a cryptic splice site in
one lamin A gene. The splicing error removes the coding region
for the ZMPSTE24 cleavage site from prelamin A, resulting in the
production of a mutant form of lamin A called progerin that is
farnesylated and carboxylmethylated, but unable to be cleaved by
ZMPSTE24. Children with HGPS begin to manifest symptoms of
accelerated aging between 1–2 years of age, and often succumb to
stroke at an average age of 13 years [22]. HGPS as well as the
other progeroid disorders highlight the importance of the
ZMPSTE24 cleavage of prelamin A for human health.
Inhibition of prelamin A processing by ZMPSTE24 may have
additional relevance to human health. Certain protease inhibitor
drugs that target the aspartyl protease of HIV have also been
shown to inhibit ZMPSTE24, an undesirable side effect for which
the mechanism remains unclear, and which may contribute to the
lipodystrophy and metabolic disorder side effects experienced by
patients who have used these medications as part of a long term
treatment regimen [23–26]. In vascular smooth muscle cells from
older individuals, ZMPSTE24 cleavage of prelamin A is
diminished, which could contribute to the cardiovascular issues
associated with normal physiological aging [27].
Because ZMPSTE24 activity is critical for human health and
longevity, it is important to determine the substrate requirements
of prelamin A cleavage by the ZMPSTE24 enzyme. Here, we
have examined several aspects of the prelamin A substrate that are
required for recognition and proteolysis by ZMPSTE24. We find
that the last 41 amino acids of the C-terminus are sufficient for
efficient cleavage, while 31 amino acids are not, and furthermore
that particular residues within this region, including some in the
vicinity of the cleavage site, contribute to recognition and cleavage
by ZMPSTE24, while other residues do not appear to be critical.
We also provide evidence that insertion of a spatial linker between
the cleavage site and the farnesyl-carboxylmethyl cysteine can
negatively impact cleavage efficiency. These studies begin to define
the characteristics of an enzymatic cleavage event underlying
several human progeroid disorders.
Results
ZMPSTE24 plays an important role in cleaving the tail from
prelamin A. However, little is known about substrate recognition
except that farnesylation appears to be a critical requirement
[9,28]. Preventing ZMPSTE24 cleavage by inhibiton of CAAX
processing can be achieved by the use of farnesyltransferase
inhibitors (FTIs), or by mutation of the CAAX cysteine (C661S)
(Figure 1B, top panel) [13,29–32]. While the importance of
farnesylation of the CAAX cysteine has been well-established, it
has yet to be determined whether the farnesyl group is required
specifically for ZMPSTE24 recognition, binding and/or cleavage,
or in a more indirect manner for promotion of prelamin A
membrane association where ZMPSTE24 resides. It is also
important to note that farnesylation is required for all subsequent
lamin A processing to occur, including endoproteolytic removal of
the terminal AAX residues and carboxylmethylation.
To determine the impact on prelamin A cleavage due to lack of
individual CAAX processing enzymes, we examined MEFs
derived from mouse genetic knockouts of Rce1 or Icmt, encoding
the AAX’ing and carboxylmethylation enzymes, respectively, as
compared to Zmpste24 knockout MEFs. MEFs that are Rce12/2
are unaffected in prelamin A maturation (Figure 1B, middle
panel), consistent with the observation that RCE1 and
ZMPSTE24 are functionally redundant for this step (C. Hrycyna,
S. Michaelis, unpublished). In MEFs that are Icmt2/2, the lack of
carboxylmethylation modestly reduces the efficiency of prelamin A
Figure 1. Assessing ZMPSTE24-mediated cleavage of the tail from prelamin A in cells blocked at different steps of CAAX
processing. A) Schematic of the post-translational processing pathway for lamin A. Lamin A is synthesized as a precursor, prelamin A, and
undergoes CAAX processing (farnesylation, AAX’ing, and carboxylmethylation; steps 1–3), followed by ZMPSTE24-mediated cleavage of the
farnesylated, carboxylmethylated tail (step 4). B) An NIH 3T3 stable cell line expressing GFP-lamin A was treated with and without farnesyltransferase
inhibitor (FTI). Lysates from these cells were compared to lysates prepared from NIH 3T3 stable cell line expressing GFP-lamin A with a mutation of
the CAAX cysteine to serine (C661S) on an 8% SDS-PAGE gel (step 1 block). Lysates prepared from WT MEFs and MEFs containing knockouts of the
indicated genes (Rce1, Icmt, and Zmpste24; S. Young, UCLA) were run on 8% gels and probed with antibodies to detect endogenous lamin A. The
forms of lamin A are indicated: M (mature), PLA (prelamin A), and PLA(NF) (prelamin A, non-farnesylated).
doi:10.1371/journal.pone.0032120.g001
Proteolytic Cleavage of Prelamin A by ZMPSTE24
PLoS ONE | www.plosone.org 2 February 2012 | Volume 7 | Issue 2 | e32120cleavage, but clearly does not significantly block it, in contrast to
the case in Zmpste242/2 MEFs where cleavage is completely
blocked (Figure 1; compare middle panel to bottom panel). This
result suggests that while the farnesyl group is absolutely required
for cleavage (Figure 1B top), the carboxylmethyl group is not
essential, although the efficiency of cleavage by ZMPSTE24 is
slightly reduced in its absence, as observed here and also noted
elsewhere [6,13], and may reflect a kinetic delay (Figure 1B,
middle).
The last 41 amino acids of prelamin A are sufficient for
efficient cleavage by ZMPSTE24, while 31 amino acids are
not
We sought to identify the minimal region of the prelamin A C-
terminus that contains all critical context for ZMPSTE24-
mediated cleavage of the prelamin A tail. The full length prelamin
A precursor is 664 amino acids long, and contains several defining
features: an N-terminal globular head followed by coiled-coil
domains, a nuclear localization sequence (NLS), an IgG fold, and
a CAAX motif (Figure 2A). Previous work has shown that the
coiled-coil domains (located within amino acids 1–388 of lamin A)
are not required for CAAX processing and ZMPSTE24-mediated
cleavage [33,34].
We tested increasingly smaller segments of the C-terminus for
cleavage by ZMPSTE24 by designing a series of C-terminal
GFP-tagged lamin A constructs that contain GFP, the lamin A
NLS, and increasingly smaller portions of the region between
the NLS and the ZMPSTE24 cleavage site (Figure 2A). For each
deletion construct, we also made mature (MAT) and unclea-
vable (UC) versions, with MAT containing a STOP codon after
Y646 and UC containing a previously reported L647R mutation
that blocks removal of the lamin A tail [35], to use as size
controls for proper processing on our gels. We transfected the
constructs into HEK293A cells and monitored cleavage to the
mature form by Western blot analysis (Figure 2B). We found
that the 51mer and 41mer constructs were efficiently converted
to mature lamin A. Cleavage could still be detected with
deletion of an additional 10 amino acids (31mer), however the
efficiency of cleavage is reduced by about half in this context.
Notably, deletion of two additional residues (29mer) effectively
abolishes cleavage by ZMPSTE24 (Figure 2B). While it is
possible that fusion to GFP may create a steric hindrance, and
that even fewer residues may actually be required, we can
conclude from our results that the complete context required for
efficient ZMPSTE24 cleavage is contained within the last 41
amino acids of the prelamin A tail.
Replacement of C-terminal residues does not block
cleavage by ZMPSTE24
It is unclear how the farnesyl group on the CAAX cysteine (and
to a far lesser extent the carboxylmethyl group) can influence
ZMPSTE24-mediated processing at its cleavage site 15 amino
acids away. We wished to further probe whether other information
within the C-terminal tail of prelamin A, or the length of the tail
between the CAAX motif and the cleavage site, has an impact on
ZMPSTE24 cleavage. We first investigated whether the prelamin
A sequence immediately upstream of the CAAX motif is required
for ZMPSTE24 cleavage. We utilized an epitope replacement
strategy, convenient for introducing a random sequence while
maintaining the distance between the CAAX motif and the
cleavage site, by replacing nine amino acids immediately
preceding the CAAX motif with the nine amino acid HA epitope
(Figure 3). As a basis for the construct, we used the GFP-51mer,
for which there is no defect in cleavage. We found that when the
HA epitope was used to replace the C-terminal sequence, the
cleavage of prelamin A was only very slightly impacted (Figure 3).
Importantly, cleavage of the HA epitope replacement protein is
blocked in the presence of FTI and in the L647R version of the
HA replacement, indicating that the proteolytic cleavage we
observe is ZMPSTE24-dependent. Since 9 of the 15 amino acids
within the cleaved tail can be arbitrarily replaced without causing
a significant impact on ZMPSTE24 cleavage, we conclude that
Figure 2. The last 41 amino acids of prelamin A are sufficient for efficient cleavage of prelamin A by ZMPSTE24. A) Schematic
representation of full length prelamin A, and the deletion set analyzed here. Each deletion consists of GFP fused to the NLS of prelamin A (residues
416–423) and sequentially shorter C-terminal sequences (the cleaved tail encompasses the 15 residues 647–661; prior AAX’ing removes 662–664). B)
Analysis of ZMPSTE24-mediated cleavage of the prelamin A deletion constructs. The deletion constructs were transiently transfected into HEK293A
cells, and lysates were prepared 24 hours post-transfection. Proteins were resolved on 12% SDS-PAGE gels. For each deletion, mature (MAT) and
uncleavable (UC; L647R) versions were included in the analysis to serve as markers for the migration of cleaved and uncleaved versions of each
deletion, respectively.
doi:10.1371/journal.pone.0032120.g002
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cleavage of prelamin A by ZMPSTE24.
Increasing the distance between the CAAX box and the
cleavage site reduces the cleavage efficiency of prelamin
A
We considered the possibility that ZMPSTE24 might have a
‘‘molecular reach’’ capacity, binding to a farnesylated and
carboxylmethylated cysteine and cleaving within a certain distance
away, as long as an allowable cleavage site is present. Thus, we
investigated whether increasing the distance between the CAAX
box and the cleavage site could impact cleavage by creating a
construct that contained a duplication of the 9 ‘‘non-critical’’
amino acids we previously replaced with an HA epitope. This
construct, designated LA 2X, showed a significant block in
cleavage (albeit not 100% complete) (Figure 4). The residual
cleavage that did occur must be ZMPSTE24-dependent, since the
L647R mutation completely abolished it. Thus, increasing the
length of the prelamin A tail interferes significantly with cleavage
at the normal site. This result suggests a model for prelamin A
cleavage in which ZMPSTE24 seeks an appropriate cleavage site
within an allowable distance from the farnesyl-cysteine. It could
also be the case that physical attributes of the duplicated region
itself impede access to the motif (i.e. due to a physical barrier,
created by secondary structure or rigidness). This possibility seems
unlikely, however, since we have simply duplicated a region
already present within the tail. In addition, we found that insertion
of a myc epitope immediately upstream of the CAAX motif also
significantly blocks cleavage (Figure S1). Regardless of the exact
mechanism at work, we conclude that increasing the number of
residues between the cleavage site and the CAAX motif can have a
detrimental impact on cleavage efficiency by ZMPSTE24.
Analysis of the residues surrounding the cleavage site by
limited mutagenesis reveal a contextual requirement for
proteolysis by ZMPSTE24
Most proteases recognize specific residues at, flanking, or near
their cleavage site. ZMPSTE24 appears to recognize a specific
cleavage site, based at least in part on sequence, as suggested by
the L647R (UC) mutation. Importantly, our finding that cleavage
is impaired by the presence of additional residues between the
farnesyl-cysteine and the cleavage site suggests that ZMPSTE24
does not simply cleave a certain distance from the CAAX motif,
and thus is not simply a ‘‘molecular ruler’’.
In order to find additional residues that may contribute to
cleavage specificity, we performed a limited mutagenesis analysis
on the region immediately flanking the Y646 and L647 cleavage
site residues. We mutated residues R644 to S651 in the GFP-
51mer to either arginine (R) or alanine (A), and assayed for the
ability of ZMPSTE24 to cleave the lamin A tail by transient
transfection of HEK293A cells with these constructs, run side by
side with mature (MAT) and L647R (UC) versions as controls
(Figure 5). In addition to the previously established L647R (UC),
we found L648A and N650A as additional mutations that affect
cleavage of the tail by ZMPSTE24. L648A completely blocks tail
cleavage, while N650A is only partially defective for cleavage.
None of the other R or A mutations tested block cleavage of the
tail (Figure 5, and data not shown). It is notable that it is not simply
the residue, but the particular amino acid change that is made that
appears to be important, (i.e. L648R is unaffected, while L648A is
blocked in cleavage). Thus, a more comprehensive mutagenic
analysis will be required to fully elucidate the sequence motif that
is recognized by ZMPSTE24.
The R644 residue is mutated to cysteine in several human
diseases with diverse phenotypes, including a case of atypical
progeria [36–38]. Thus, the R644 residue may be important for
promoting cleavage by ZMPSTE24. Because the R644A mutation
did not affect cleavage in our assay, we recreated the R644C
disease mutation and examined the ability of this mutant to be
cleaved. Interestingly, we find a partial cleavage defect when the
Figure 3. Replacing the nine C-terminal tail residues immediately preceding the CAAX motif does not significantly inhibit cleavage
by ZMPSTE24. Within the GFP-51mer, nine amino acids immediately upstream of the CAAX motif (underlined) were replaced with a nine amino
acid long HA epitope and transiently transfected into HEK293A cells. A construct including an uncleavable (UC; L647R) version of the HA swap
construct was generated and included as a marker for migration for cleavage inhibition, in addition to FTI treatment. The NF (non-farnesylated) as
well as the uncleaved and the cleaved forms are indicated.
doi:10.1371/journal.pone.0032120.g003
Figure 4. Increasing the spacing between the CAAX motif and
the tail cleavage site affects prelamin A cleavage by
ZMPSTE24. In order to increase the linear distance between the tail
cleavage site and the CAAX cysteine, the nine amino acid sequence
upstream of the CAAX motif (SPRTQSPQN) was duplicated within the
GFP-51mer. A version of this construct bearing the uncleavable (UC;
L647R) mutation was also generated as a marker for migration of
uncleaved species. Constructs were transiently transfected into
HEK293A cells and analyzed as in Figure 2.
doi:10.1371/journal.pone.0032120.g004
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HEK293A cells (Figure 5). The partial inhibition of cleavage that
results from this mutation suggests that R644 is an important
contributing residue for efficient ZMPSTE24 cleavage, along with
L648 and N650.
Discussion
The proteolytic processing and cleavage of the prelamin A tail is
critical for lamin A function. Several progeroid disorders result
from mutations in the genes encoding lamin A or ZMPSTE24 that
interfere with the final proteolytic event that removes the modified
tail [14,17,39–41]. The symptoms associated with these diseases
range in severity and appear to correlate with the extent of the
lamin A cleavage defect such that the greater the amount of
uncleaved persistently prenylated prelamin A that accumulates,
the more severe the disease. For example, a partial reduction in
ZMPSTE24 activity results in diseases that manifest later than
HGPS (MAD-B) [42,43], while mutations that more extensively
impact prelamin A cleavage result in the accelerated aging
phenotype of the childhood progeria disease HGPS [44]. The
complete loss of any ZMPSTE24 cleavage activity results in
neonatal lethality (RD), thus underscoring the vital importance of
ZMPSTE24 to human health [19,45].
The permanently prenylated form of lamin A appears to confer
a dominant negative function to lamin A, altering its membrane
binding characteristics and negatively impacting many nuclear
functions. Thus, drug therapeutic intervention strategies for HGPS
have been designed to target and inhibit the prenylation of
prelamin A by the use of FTIs [46]. The goal of the drug therapy is
to prevent the addition of the hydrophobic CAAX modifications
and thus reduce the toxicity of the aberrant protein. It is clear that
an understanding of the ZMPSTE24-mediated proteolytic event
that normally removes the prenylated lamin A tail is critical to
inform future therapeutic strategies, in particular for those diseases
resulting from mutations in ZMPSTE24 itself that impair
enzymatic activity. Lack of ZMPSTE24-mediated cleavage of
prelamin A may also contribute to normal physiological aging,
thus further highlighting the importance of understanding the
molecular details of this processing step [27].
Despite the importance of enzymatic cleavage of the prelamin A
tail, ZMPSTE24 activity toward prelamin A remains largely
uncharacterized. Sequence alignments with multiple lamin A
homologues known to undergo cleavage (human, mouse, and
chicken) [12,33,35] reveal that the region surrounding the
cleavage site is well-conserved (Figure S2). In this study we have
examined several essential features of ZMPSTE24-mediated
prelamin A tail cleavage, and our results are summarized in
Figure 6. We found that the 41 amino acid tail of prelamin A is
sufficient for efficient ZMPSTE24 cleavage (Figure 2), and that
mutation of certain residues near the cleavage site can influence
cleavage (Figure 5). Importantly, for each of the residues for which
a particular change partially or completely blocked cleavage by
ZMPSTE24 (R644, L647, L648 and N650), we found another
change(s) to have no effect. The fact that a certain residue at a
particular position relative to the cleavage site is allowable while
another is not (i.e. L648R is cleaved, while L648A is not) suggests
that cleavage is not strictly dependent on the presence of a
particular amino acid and that a consensus motif may remain to be
defined. We have also found that increasing the distance between
the CAAX motif and the cleavage site reduces cleavage efficiency
(Figure 4). This result argues against the possibility that
ZMPSTE24 may simply act as a ‘‘molecular ruler’’ that cleaves
a measured distance from the CAAX motif.
Figure 5. Mutagenesis of the residues surrounding the tail cleavage site reveals a contextual requirement and evidence for a
consensus motif for the cleavage of prelamin A by ZMPSTE24. The indicated residues upstream and downstream of the cleavage site
(between Y646 and L647) within the GFP-51mer were mutated to either alanine (A) or arginine (R) and assayed for cleavage by ZMPSTE24 by
transient transfection into HEK293A cells. The R644C mutation was also included based on its reported presence in atypical progeria and other
diseases as discussed in the text. Amino acid changes that do and do not impact cleavage are indicated. Gel analysis of mutants that impair cleavage
is shown.
doi:10.1371/journal.pone.0032120.g005
Figure 6. Summary of the critical features found in this study
for ZMPSTE24-mediated cleavage of the prelamin A tail. Within
the terminal 41 amino acids (residues 624–664) shown here to be
needed for efficient cleavage (Figure 2), three new residues in addition
to L647 (L647R=UC) were identified in this study that contribute to an
apparent sequence requirement in the region of the cleavage site
(R644, L648, and N650) (Figure 5). The identity of the nine amino acids
(SPRTQSPQN) upstream of the CAAX motif appears not to be critical for
cleavage (Figure 3). Placing the cleavage site at a further distance from
the CAAX motif was found to inhibit cleavage by ZMPSTE24 (Figure 4),
suggesting that a critical length from the farnesyl-cysteine may be
tolerated by ZMPSTE24. Farnesylation is critical for further processing
and cleavage by ZMPSTE24, while carboxylmethylation only modestly
contributes to cleavage efficiency (Figure 1).
doi:10.1371/journal.pone.0032120.g006
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‘‘spatial requirement’’ between two important substrate features
(the prenylated cysteine and the cleavage site). First, the CAAX
modifications promote membrane association of the prelamin A
substrate. It is possible that ZMPSTE24, which is a transmem-
brane protein with its HEXXH zinc metalloprotease domain in a
cytosolic/nucleoplasmic loop [14], can interact with the prelamin
A cleavage site only within a limited distance from the site of
membrane attachment of prelamin A through its farnesylated
cysteine (Figure 6). Thus, the addition of sequence between the
CAAX motif and the cleavage site may result in the cleavage site
being located outside of the ‘‘membrane-tethered reach’’ of
ZMPSTE24. Alternatively, ZMPSTE24 may directly recognize
and bind to the farnesyl-carboxylmethyl cysteine at one internal
binding site within ZMPSTE24, and cleave prelamin A using an
active site elsewhere in ZMPSTE24. Thus the spatial restriction
found in this study may reflect the internal ‘‘molecular reach’’
between the farnesyl recognition/binding site within ZMPSTE24
and the active proteolytic site within ZMPSTE24 that carries out
cleavage. It will be of interest to determine whether decreasing the
distance between the cleavage site and the CAAX motif would
impact ZMPSTE24 cleavage. There is currently no evidence for
separate farnesyl-binding and active sites for ZMPSTE24, and
whether farnesyl is required for cleavage directly (for binding
between prelamin A and the enzyme), or indirectly (for proper
membrane positioning of the prelamin A substrate with the
enzyme active site) remains to be determined.
The sole residue residue examined in our mutagenesis analysis
for which mutations are associated with human diseases is R644.
The R644C mutation is associated with pleiotropic disease
phenotypes, and has been identified in cases of atypical progeria
and lipodystrophy, as well as motor neuropathy, limb girdle
muscle weakness and dilated cardiomyopathy [37]. The R644H
mutation has also been reported in a case of muscular dystrophy
[47]. The association of R644C with atypical progeria and
lipodystrophy is particularly intriguing, since both disease
phenotypes can result from a failure to cleave lamin A. Given
the potential molecular mechanism that connects the range of
progeroid disorders, namely failure to cleave prelamin A, we
investigated whether prelamin A could be detected in fibroblasts
from a patient with atypical progeria with the R644C mutation
(Coriell Institute; AG00989). We found that while a very small
amount of prelamin A was detectable, the amount in these cells
was variable between experiments, and we did not consistently
observe a significant difference from wild type (data not shown). It
is worth noting that the disease phenotypes associated with R644C
are variable and mild compared to progeria, and it remains
possible that prelamin A processing could be affected in patients in
a tissue-specific manner, and thus not able to be detected in the
fibroblast sample available. Prelamin A also accumulates over time
in wild type cell lines with increased passaging, thus it remains an
open question whether the amount present in the patient cells
would significantly correlate with disease pathology.
Materials and Methods
Cell Culture Conditions
NIH 3T3 fibroblasts, HEK293A, and mouse embryonic
fibroblasts (MEFs) (Zmpste242/2, Rce12/2, and Icmt2/2
obtained from S. Young, UCLA) [12,48,49], were maintained in
DMEM (GIBCO) supplemented with 10% fetal bovine serum
(GIBCO). Farnesyltransferase inhibitor R115777 (a gift from M.
Gelb, University of Washington) was used in cell culture medium
at a final concentration of 1 mM for 24 h.
Stable and Transient Expression in Cell Culture
NIH 3T3 fibroblasts stably expressing GFP-lamin A and GFP-
lamin A C661S TetOff constructs were created by retroviral
transduction, as described previously [6]. Retrovirus was prepared
by transient co-transfection of HEK293F cells with the packaging
plasmid pCL-Eco using Fugene 6 Transfection Reagent (Roche
Applied Science, Indianapolis, IN) according to the manufactur-
er’s protocol. All other constructs in this study were expressed by
transient transfection of a HEK293A TetOff cell line, using
Fugene 6. Lysates for gel analysis were prepared 24 hours post-
transfection.
Plasmid Constructs
All plasmids were created in the pSM2277 backbone, a
retroviral pMX vector containing an inducible Tet promoter
and a hygromycin selection cassette. GFP-lamin A (pSM 2278)
and GFP-lamin A bearing the C661S mutation (pSM2308) were
described previously [6]. The series of lamin A deletion constructs
shown in Figure 2 were constructed by fusing the NLS from lamin
A (amino acids 416–423) to the C-terminus of GFP, to which was
appended increasingly shorter lengths of the lamin A C-terminus.
For each deletion, an uncleavable (UC) version (L647R) and a
mature version (STOP codon after Y646) were also generated.
The HA epitope, myc epitope, duplicated lamin A region (LA 2X),
and various lamin A mutations were all introduced into the GFP-
51mer (pSM2478) using standard cloning techniques and the
QuikChange Site Directed Mutagenesis Kit (Stratagene, La Jolla,
CA) according to the manufacturer’s instructions. The nine amino
acid HA epitope was inserted in frame to replace lamin A residues
652–660, while the LA 2X construct was created by inserting the
sequence from 652–660 between residues 660 and 661, to create a
duplicated nine amino acid region immediately upstream of the
CAAX motif. Single point mutations were introduced using the
QuikChange Site Directed Mutagenesis Kit.
Western Blotting and Antibodies
Cell lysates were made by direct lysis in SDS-PAGE sample
buffer followed by heating to 65uC for 10 min, and then were
briefly sonicated to disrupt nuclear chromatin. For detection of full
length GFP-lamin A, GFP-lamin A C661S, and endogenous lamin
A in MEFs (Figure 1), lysates were resolved on 8% SDS-PAGE
gels. For detection of the lamin A deletions, the HA epitope
replacement, the lamin A duplication (LA 2X), and the lamin A
mutants, the cell lysates were resolved on 12% SDS-PAGE gels
(Figures 2, 3, 4, and 5). Gels were transferred to nitrocellulose and
blocked using TBST (100 mM Tris-HCl, pH 8.0, 150 mM NaCl,
0.05% Tween-20) and 10% Western Blocking Reagent (Roche
Applied Science, Indianapolis, IN). Polyclonal antibodies to lamin
A (Santa Cruz, sc-6214) or a monoclonal antibody to GFP (Roche)
were used at 1:1000. Secondary antibodies used included HRP
conjugated anti-rabbit and anti-mouse (GE Healthcare, UK).
Secondary antibodies were detected using Amersham ECL Plus
Western Blotting Detection System (GE Healthcare, UK)
according to the manufacturer’s instructions. All Western blot
experiments were performed at least in triplicate, and a
representative example is shown.
Supporting Information
Figure S1 Insertion of a myc epitope between the CAAX
motif and the tail cleavage site prevents prelamin A
cleavage by ZMPSTE24. The 10 amino acid long myc epitope
was inserted immediately upstream of the CAAX motif, to create
‘‘LA Mycins’’. Constructs were transiently transfected into
Proteolytic Cleavage of Prelamin A by ZMPSTE24
PLoS ONE | www.plosone.org 6 February 2012 | Volume 7 | Issue 2 | e32120HEK293A cells and analyzed by SDS-PAGE as in Figure 2.
Uncleavable (UC) and wild type (LA) versions were included as
markers for the migration of uncleaved and mature species,
respectively. As an additional control for the migration of the
uncleaved LA Mycins species, 1 uM FTI was included to prevent
the farnesylation and cleavage of LA Mycins (last lane).
(TIF)
Figure S2 Sequence alignment of human, mouse and
chicken lamin A homologues for the 41mer region
examined in this study. Sequences have been reported for
mammals, birds and frogs, all of which show a substantial degree
of conservation, with some drift in frogs. The sequences shown
here correspond to those for which cleavage of the lamin A tail has
been experimentally demonstrated [12,33,35]. The sequence
comparison (made using ClustalW and Boxshade) is shown with
identical residues shaded in black, and conserved residues in gray.
The lamin A residues found in this study to be critical for prelamin
A cleavage are outlined in red. Likewise, the region that can be
replaced with the HA epitope without affecting cleavage is also
noted.
(TIFF)
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